SEC Form 4 filed by Nephros Inc.

10-K - NEPHROS INC (0001196298) (Filer)

8-K - NEPHROS INC (0001196298) (Filer)

10-Q - NEPHROS INC (0001196298) (Filer)

4 - NEPHROS INC (0001196298) (Issuer)

4 - NEPHROS INC (0001196298) (Issuer)

4 - NEPHROS INC (0001196298) (Issuer)

Full-Year Net Revenue Increased 33% Y-O-Y to $18.8 Million and Fourth-Quarter Net Revenue up 22% Y-O-Y to $4.7 Million Reports Second Consecutive Year of Positive Net Income SOUTH ORANGE, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. Financial HighlightsFourth Quarter Ended December 31, 2025. Net revenue was $4.7 million, compared to $3.9 million in the fourth quarter of 2024, up 22%Net income was $62,000, compared to $349,000 during the same period in 2024Adjust

SOUTH ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth-quarter financial results on Thursday, March 12, 2026 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

SOUTH ORANGE, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced its entry into the Puerto Rican market, targeting high-need applications such as ice machines, drinking fountains, bottle fillers, and sterile processing environments. With a proven track record in infection control and water purity, Nephros brings a differentiated approach to water filtration, delivering advanced products with faster service and local-language support in a region long underserved by premium filtration providers. Puerto Rico MarketWith increasing focus on public health,

Full-Year Net Revenue Increased 33% Y-O-Y to $18.8 Million and Fourth-Quarter Net Revenue up 22% Y-O-Y to $4.7 Million Reports Second Consecutive Year of Positive Net Income SOUTH ORANGE, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. Financial HighlightsFourth Quarter Ended December 31, 2025. Net revenue was $4.7 million, compared to $3.9 million in the fourth quarter of 2024, up 22%Net income was $62,000, compared to $349,000 during the same period in 2024Adjust

SOUTH ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth-quarter financial results on Thursday, March 12, 2026 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

SOUTH ORANGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 6, 2025 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv

SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment

- Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

SC 13G - NEPHROS INC (0001196298) (Subject)

SC 13G - NEPHROS INC (0001196298) (Subject)

SC 13G - NEPHROS INC (0001196298) (Subject)